HAEMOPHILUS PARASUIS SEROVAR 4, STRAIN 2170B (INACTIVATED) Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

haemophilus parasuis serovar 4, strain 2170b (inactivated)

zoetis australia pty ltd - haemophilus parasuis (serovar 4) strain 2170b - unknown - haemophilus parasuis (serovar 4) strain 2170b vaccine-microbial active 0.0 - active constituent

HAEMOPHILUS PARASUIS SEROVAR 5, STRAIN 1A84-29755 (INACTIVATED) Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

haemophilus parasuis serovar 5, strain 1a84-29755 (inactivated)

zoetis australia pty ltd - haemophilus parasuis (serovar 5) strain 1a84-29755 - unknown - haemophilus parasuis (serovar 5) strain 1a84-29755 vaccine-microbial active 0.0 - active constituent

INFANRIX-IPV+Hib powder and suspension for suspension for injection. Diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed) Malta - Ingliż - Medicines Authority

infanrix-ipv+hib powder and suspension for suspension for injection. diphtheria, tetanus, pertussis (acellular component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - pertactin, pertussis filamentous, haemagglutinin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - powder and suspension for suspension for injection - pertactin 8 µg pertussis filamentous haemagglutinin 25 µg pertussis toxoid 25 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu/0.5ml poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu/0.5ml poliovirus (inactivated) type 3 (saukett strain) 32 dagu/0.5ml diphtheria toxoid haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines

Recombitek C6/CV 1 dose of 1 ml vaccine contains: Lyophilized: Canine Distemper, Canarypox Vector, at least . . . . . . . . . . . . . . . . . . . . . . . 106.4 TCID50 Canine Adenovirus Type 2, Toronto A/26/61 strain, at least. . . . . . . . . . . . 104.3 TCID50 Canine Parainfluenza virus, D-008 strain, at least . . . . . . . . . . . . . . . . . . . 103.9 TCID50 Canine Coronavirus, K-378/51 strain, at least . . . . . . . . . . . . . . . . . . . . . . . 103.6 TCID50 Canine Parvovirus, 780916 strain, at least . . . . . . . . . . . . . . . . . . . . . . . . . . 103.3 FAID50 Liquid: Leptospira canicola, strain 1503, at least . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 NU Leptospira icterohaemorrhagiae, strain 1518, at least. . . . . . . . . . . . . . . . . . 30 NU Lyophilized Powder for Injection (IM/SC) Filippini - Ingliż - FDA (Food And Drug Administration)

recombitek c6/cv 1 dose of 1 ml vaccine contains: lyophilized: canine distemper, canarypox vector, at least . . . . . . . . . . . . . . . . . . . . . . . 106.4 tcid50 canine adenovirus type 2, toronto a/26/61 strain, at least. . . . . . . . . . . . 104.3 tcid50 canine parainfluenza virus, d-008 strain, at least . . . . . . . . . . . . . . . . . . . 103.9 tcid50 canine coronavirus, k-378/51 strain, at least . . . . . . . . . . . . . . . . . . . . . . . 103.6 tcid50 canine parvovirus, 780916 strain, at least . . . . . . . . . . . . . . . . . . . . . . . . . . 103.3 faid50 liquid: leptospira canicola, strain 1503, at least . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 nu leptospira icterohaemorrhagiae, strain 1518, at least. . . . . . . . . . . . . . . . . . 30 nu lyophilized powder for injection (im/sc)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - modified live recombinant canine distemper virus (cdv) , canine adenovirus type 2 (cav-2) , canine parvovirus (cpv) , canine parainfluenza virus (cpiv) , canine coronavirus (ccv) , inactivated leptospira interrogans ser. canicola , leptospira interrogans ser. icterohaemorrhagiae vaccine (vet.) - lyophilized powder for injection (im/sc) - 1 dose of 1 ml vaccine contains: lyophilized: canine distemper, canarypox vector, at least . . . . . . . . . . . . . . . . . . . . . . . 106.4 tcid50 canine adenovirus type 2, toronto a/26/61 strain, at least. . . . . . . . . . . . 104.3 tcid50 canine parainfluenza virus, d-008 strain, at least . . . . . . . . . . . . . . . . . . . 103.9 tcid50 canine coronavirus, k-378/51 strain, at least . . . . . . . . . . . . . . . . . . . . . . . 103.6 tcid50 canine parvovirus, 780916 strain, at least . . . . . . . . . . . . . . . . . . . . . . . . . . 103.3 faid50 liquid: leptospira canicola, strain 1503, at least . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 nu leptospira icterohaemorrhagiae, strain 1518, at least. . . . . . . . . . . . . . . . . . 30 nu

Suigen PRDC Formulation: Each 1 mL (dose) contains: Bordetella bronchiseptica -1 OD Bordetella bronchiseptica (DNT)-200 ug/mL Pasteurella multocida (Type A and D)-I OD P. multocida Type A (OMP)-30 ug/mL Actinobacillus pleuropneumoniae (Serotype 2 and 5)-1 OD P. multocida Type D (DNT)-200 ug/mL Mycoplasma hvopneumoniae-0.12 OD A. pleuropneumoniae Serotype 2 and 5 (Toxin) 10 ug/mL Streptococcus suis (Type 2)-0.45 OD Haemophilus parasuis (Serotype 1, 4 and 5)-0.45 OD OD - Optical Density at 410 nm absorbance (ELISA) DNT – Dermonecrotic Toxin OMP - Outer Membrane Protein Suspension for Injection (IM) Filippini - Ingliż - FDA (Food And Drug Administration)

suigen prdc formulation: each 1 ml (dose) contains: bordetella bronchiseptica -1 od bordetella bronchiseptica (dnt)-200 ug/ml pasteurella multocida (type a and d)-i od p. multocida type a (omp)-30 ug/ml actinobacillus pleuropneumoniae (serotype 2 and 5)-1 od p. multocida type d (dnt)-200 ug/ml mycoplasma hvopneumoniae-0.12 od a. pleuropneumoniae serotype 2 and 5 (toxin) 10 ug/ml streptococcus suis (type 2)-0.45 od haemophilus parasuis (serotype 1, 4 and 5)-0.45 od od - optical density at 410 nm absorbance (elisa) dnt – dermonecrotic toxin omp - outer membrane protein suspension for injection (im)

virbac philippines inc.; distributor: virbac philippines inc. - inactivated bordetella bronchiseptica , pasteurella multocida , actinobacillus pleuropneumoniae , mycoplasma hyopneumoniae , streptococcus suis , haemophilus parasuis vaccine (vet.) - suspension for injection (im) - formulation: each 1 ml (dose) contains: bordetella bronchiseptica -1 od bordetella bronchiseptica (dnt)-200 ug/ml pasteurella multocida (type a and d)-i od p. multocida type a (omp)-30 ug/ml actinobacillus pleuropneumoniae (serotype 2 and 5)-1 od p. multocida type d (dnt)-200 ug/ml mycoplasma hvopneumoniae-0.12 od a. pleuropneumoniae serotype 2 and 5 (toxin) 10 ug/ml streptococcus suis (type 2)-0.45 od haemophilus parasuis (serotype 1, 4 and 5)-0.45 od od - optical density at 410 nm absorbance (elisa) dnt – dermonecrotic toxin omp - outer membrane protein

Hydrophilic Cream "NIKKO" (親水クリーム「ニッコー」) Ġappun - Ingliż - すりの適正使用協議会 RAD-AR Council, Japan

hydrophilic cream "nikko" (親水クリーム「ニッコー」)

maruishi pharmaceutical. co., ltd. - hydrophilic cream - white ointment

Hydrophilic Ointment "TOHO" (親水クリーム「東豊」) Ġappun - Ingliż - すりの適正使用協議会 RAD-AR Council, Japan

hydrophilic ointment "toho" (親水クリーム「東豊」)

nichi-iko pharmaceutical co.,ltd - hydrophilic cream - white ointment

Hydrophilic Petrolatum (親水ワセリン) Ġappun - Ingliż - すりの適正使用協議会 RAD-AR Council, Japan

hydrophilic petrolatum (親水ワセリン)

maruishi pharmaceutical. co., ltd. - hydrophilic petrolatum - white ointment

RESPISURE HPS VACCINE (INACTIVATED) Awstralja - Ingliż - APVMA (Australian Pesticides and Veterinary Medicines Authority)

respisure hps vaccine (inactivated)

zoetis australia pty ltd - haemophilus parasuis; thiomersal - misc. vaccines or anti sera - haemophilus parasuis vaccine active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - glassers disease | haemophilus parasuis serovar 13 | haemophilus parasuis serovar 4 | haemophilus parasuis serovar 5 | polyserositis

Act-HIB vaccine New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

act-hib vaccine

pharmacy retailing (nz) ltd t/a clinect nz pty ltd - haemophilus influenzae type b vaccine 10ug (conjugated to tetanus protein (18-30µg)) - injection with diluent - 10 mcg/0.5ml - active: haemophilus influenzae type b vaccine 10ug (conjugated to tetanus protein (18-30µg)) excipient: hydrochloric acid sucrose trometamol sodium chloride water for injection - act-hib is indicated for use in infants from 2 months to 5 years of age for active immunisation against invasive disease caused by the haemophilus influenzae type b.